Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials

References

• VestboJHurdSSAgustiAGGlobal strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summaryAm J Respir Crit Care Med2013187434736522878278
   PubMed Web of Science ®Google Scholar
• American Thoracic SocietyDyspnea. Mechanisms, assessment, and management: a consensus statement. American Thoracic SocietyAm J Respir Crit Care Med199915913213409872857
   PubMed Web of Science ®Google Scholar
• ParshallMBSchwartzsteinRMAdamsLAn official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspneaAm J Respir Crit Care Med2012185443545222336677
   PubMed Web of Science ®Google Scholar
• MahlerDAWeinbergDHWellsCKThe measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexesChest19848567517586723384
   PubMed Web of Science ®Google Scholar
• MahlerDAWitekTJJrThe MCID of the transition dyspnea index is a total score of one unitCOPD2005219910317136969
   PubMedGoogle Scholar
• JonesPWMahlerDAGaleRProfiling the effects of indacaterol on dyspnoea and health status in patients with COPDRespir Med2011105689289921397482
   PubMed Web of Science ®Google Scholar
• JonesPWSinghDBatemanEDEfficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN studyEur Respir J201240483083622441743
   PubMed Web of Science ®Google Scholar
• KaplanAEffect of tiotropium on quality of life in COPD: a systematic reviewPrim Care Respir J201019431532521042697
   PubMedGoogle Scholar
• MahlerDAWellsCKEvaluation of clinical methods for rating dyspneaChest19889335805863342669
   PubMed Web of Science ®Google Scholar
• NanniniLCatesCJLassersonTJCombined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20074CD00379417943798
   PubMed Web of Science ®Google Scholar
• GrootendorstDCGauwSAVerhooselRMReduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPDThorax200762121081108717573446
   PubMed Web of Science ®Google Scholar
• O’DonnellDEHyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary diseaseProc Am Thorac Soc20063218018416565429
   PubMedGoogle Scholar
• CalverleyPMRabeKFGoehringUMRoflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trialsLancet2009374969168569419716960
   PubMed Web of Science ®Google Scholar
• CalverleyPMSanchez-TorilFMcIvorAEffect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2007176215416117463412
   PubMed Web of Science ®Google Scholar
• RennardSICalverleyPMGoehringUMReduction of exacerbations by the PDE4 inhibitor roflumilast – the importance of defining different subsets of patients with COPDRespir Res2011121821272339
   PubMed Web of Science ®Google Scholar
• CazzolaMMacNeeWMartinezFJOutcomes for COPD pharmacological trials: from lung function to biomarkersEur Respir J200831241646918238951
   PubMed Web of Science ®Google Scholar
• HigginsJPThompsonSGQuantifying heterogeneity in a meta-analysisStat Med200221111539155812111919
   PubMed Web of Science ®Google Scholar
• HalpinDMTashkinDPDefining disease modification in chronic obstructive pulmonary diseaseCOPD20096321122519811377
   PubMedGoogle Scholar
• JonesPWDonohueJFNedelmanJCorrelating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysisRespir Res20111216122206353
   PubMed Web of Science ®Google Scholar
• MahlerDAWardJWatermanLAPatient-reported dyspnea in COPD reliability and association with stage of diseaseChest200913661473147919696126
   PubMed Web of Science ®Google Scholar
• WestwoodMBourbeauJJonesPWRelationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic reviewRespir Res2011124021477298
   PubMed Web of Science ®Google Scholar
• CasaburiRMahlerDAJonesPWA long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary diseaseEur Respir J200219221722411866001
   PubMed Web of Science ®Google Scholar
• DahlRChungKFBuhlREfficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPDThorax201065647347920522841
   PubMed Web of Science ®Google Scholar
• KerwinEHebertJGallagherNEfficacy and safety of NVA237 versus placebo and tiotropium in patients with moderate-to-severe COPD over 52 weeks: The GLOW2 studyEur Respir J20124051106111423060624
   PubMed Web of Science ®Google Scholar
• WatsonLSchoutenJPLofdahlCGPredictors of COPD symptoms: does the sex of the patient matter?Eur Respir J200628231131816707516
   PubMed Web of Science ®Google Scholar
• AmbrosinoNFoglioKBalzanoGTiotropium and exercise training in COPD patients: effects on dyspnea and exercise toleranceInt J Chron Obstruct Pulmon Dis20083477178019281092
   PubMedGoogle Scholar
• Forest Research Institute Core Presentation for the April 7, 2010 meeting of the Pulmonary-Allergy Drugs Advisory Committee Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM208711.pdfAccessed April 1, 2013
   Google Scholar
• RabeKFBatemanEDO’DonnellDRoflumilast – an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trialLancet2005366948556357116099292
   PubMed Web of Science ®Google Scholar
• RennardSISunSXTourkodimitrisSEffect of roflumilast treatment added to tiotropium on dyspnea in patients with chronic obstructive pulmonary disease [abstract]Am J Respir Crit Care Med2012185A2261
   Google Scholar
• EakinEGResnikoffPMPrewittLMValidation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San DiegoChest199811336196249515834
   PubMed Web of Science ®Google Scholar
• FabbriLMCalverleyPMIzquierdo-AlonsoJLRoflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trialsLancet2009374969169570319716961
   PubMed Web of Science ®Google Scholar
• PanLGuoYZZhangBDoes roflumilast improve dyspnea in patients with chronic obstructive pulmonary disease? A meta-analysisJ Thorac Dis20135442242923991297
   PubMed Web of Science ®Google Scholar
• CurtisJRDeyoRAHudsonLDPulmonary rehabilitation in chronic respiratory insufficiency. 7. Health-related quality of life among patients with chronic obstructive pulmonary diseaseThorax19944921621708128407
   PubMed Web of Science ®Google Scholar
• HajiroTNishimuraKTsukinoMA comparison of the level of dyspnea vs disease severity in indicating the health-related quality of life of patients with COPDChest199911661632163710593787
   PubMed Web of Science ®Google Scholar
• JonesPWQuirkFHBaveystockCMThe St George’s Respiratory QuestionnaireRespir Med199185Suppl B25311759018
   PubMed Web of Science ®Google Scholar
• RennardSCalverleyPMASunSXEffect of roflumilast treatment on health-related quality of life in patients with chronic obstructive pulmonary disease [abstract]Respir Care2011101641
   Google Scholar
• JenkinsCRCelliBAndersonJASeasonality and determinants of moderate and severe COPD exacerbations in the TORCH studyEur Respir J2012391384521737561
   PubMed Web of Science ®Google Scholar
• FranssenFMSpruitMAWoutersEFDeterminants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis2011649350122069360
   PubMed Web of Science ®Google Scholar